AT
Aditya Tolia
Private Equity Senior Analyst
OrbiMed
Private Equity Senior Analyst at OrbiMed with prior Investec and PwC banking experience.
Bio
Professional summary
Ran Geng joined OrbiMed in 2021 and is a Principal on the Private Equity team. Before OrbiMed, she was Vice President in biotech venture investments at Matrix Partners China and earlier consulted at ZS Associates on M&A and clinical-development strategy for Roche/Genentech, Gilead, and Novartis. Forbes reported that she had led investments including ArriVent Biopharma, Nikang Therapeutics, and Senti Biosciences.
Notable companies
Selected portfolio companies the partner has backed
ArriVent BiopharmaNikang TherapeuticsSenti BiosciencesChameleon Biosciences
Background
Career, education, and skills
Career history
- OrbiMedPrincipal, Private Equity2021 – Present
- Matrix Partners ChinaVice President, Biotech Venture Investments
- ZS AssociatesConsultant
Education
- Stanford UniversityM.S., Biomedical Informatics
- University of PennsylvaniaB.A., Computational Biology
- Wharton School, University of PennsylvaniaB.S.E., Operations Management
Other partners at OrbiMed
12 more profiles
Alexis Megibow
Private Equity Associate
OrbiMed
Private Equity Associate at OrbiMed.
Ankesh Bhansali
Managing Director
OrbiMed
OrbiMed Asia Managing Director focused on healthcare private equity.
Arun Sadhanandham
Managing Director
OrbiMed
OrbiMed Asia Managing Director investing in healthcare private equity.
BC
Brendan Weber, CFA
Principal
OrbiMed
Principal on OrbiMed's Credit & Royalty team focused on structured credit and royalty financings.
CG
Carl Gordon
Managing Partner
OrbiMed
OrbiMed Managing Partner leading private equity and biotech company formation.
Carl L. Gordon
Managing Partner
OrbiMed
Carl L. Gordon is a Managing Partner at OrbiMed and leads the firm's private equity team.
CN
Carter Neild
Managing Partner
OrbiMed
OrbiMed Managing Partner focused on healthcare royalties and Asia private investments.
Clay Daniel DeMarcus
Principal
OrbiMed
Principal focused on medical technology and non-therapeutics venture investing.
CS
Cooper Steputis
Private Equity / Venture Capital
OrbiMed
Healthcare private equity and venture investor with prior investment banking experience.
Daniel Ying
Executive Director
OrbiMed
OrbiMed Asia Executive Director focused on pharma and biotech investments.
David Bonita
General Partner
OrbiMed
OrbiMed General Partner and physician-investor in healthcare and therapeutics.